Last reviewed · How we verify
NCT01369719
Efficacy and Safety of Desferal Versus Osveral in Transfusional Iron Overload Patients With β-Thalassemia and Intermediate Thalassemia in Bandarabbas
NA trial testing osveral in Thalassemia in 138 participants. Completed in 1 May 2011.
1 January 2011
Quick facts
| Lead sponsor | Hormozgan University of Medical Sciences |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 138 |
| Start date | 1 February 2010 |
| Primary completion | 1 January 2011 |
| Estimated completion | 1 May 2011 |
| Sites | 1 location across Iran |
Drugs / interventions tested
Conditions studied
- Thalassemia — all drugs for Thalassemia →
- Iron Overload — all drugs for Iron Overload →
- Transfusion Related Complications — all drugs for Transfusion Related Complications →
Sponsor
Hormozgan University of Medical Sciences
Who can join
2 and older, any sex, with Thalassemia or Iron Overload. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Ferritin level
Time frame: 8 months
ferritin level in months 4 and 8 of the study
Sponsor's own description
Thalassemic patients often suffer from iron overload due to frequent blood transfusion. Oral iron chelators reduce iron overload in transfusion dependent patients. The aim of this study is to compare the efficacy and safety of osveral and desferal in transfusional iron overload patients with β-Thalassemia and intermediate Thalassemia in Bandarabbas.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Iron homeostasis and ferroptosis in human diseases: mechanisms and therapeutic prospects.
Ru Q, Li Y, Chen L, Wu Y, et al · · 2024 · cited 365× · PMID 39396974 · DOI 10.1038/s41392-024-01969-z
Verify or expand the search:
- PubMed search for NCT01369719
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Thalassemia
Currently open trials in the same condition.
- NCT06609226 — A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia · Phase 3 · recruiting
- NCT07064941 — Effect of Exercise on Body Composition and Bone Health in Patients With Thalassemia · NA · recruiting
- NCT06800495 — Development of THALEA Kit and Its Impact on Knowledge, Attitude, and Intention for Premarital Thalassemia Screening · NA · active not recruiting
- NCT06313398 — Determination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling · EARLY_PHASE1 · recruiting
- NCT05736419 — A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an · Phase 2 · recruiting
Other Hormozgan University of Medical Sciences trials
Trials by the same sponsor.
- NCT06670573 — The Relationship Between Allergic Rhinitis, Forward Head Posture, and Anxiety Levels in Iranian Children · completed
- NCT06677684 — The Effect of Adjunct Vitamin a on Community-Acquired Pneumonia in Southern Iranian Children: a Randomized Clinical Tria · NA · completed
- NCT06665503 — The Impact of Zinc and Probiotics in Preventing Pediatric Antibiotic-Associated Diarrhea in Southern Iran · NA · completed
- NCT03266913 — Efficacy and Safety of Probiotics in Neonatal Hyperbilirubinemia · Phase 3 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01369719 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hormozgan University of Medical Sciences
- Last refreshed: 13 June 2011
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01369719.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing